Business Wire

IL-FOURKITES

14.3.2024 12:31:31 CET | Business Wire | Press release

Share
FourKites Elevates Executives to Drive Industry Adoption and Accelerate Customer Value

Leading real-time supply chain visibility provider FourKites® today announced the promotion of Priya Rajagopalan to President of Product, Technology and Operations, as well as the appointment of Ron Richardson as Chief Revenue Officer (CRO). These appointments underscore FourKites’ focus on rapid growth and innovation, with an eye toward solving customers’ most pressing needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314808596/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites promotes Priya Rajagopalan to President of Product, Technology and Operations and appoints Ron Richardson as Chief Revenue Officer to drive industry adoption and accelerate customer value (Photo: Business Wire)

Priya Rajagopalan leads FourKites’ Product, Engineering and Customer functions, with the goal of aligning customer needs and the company’s innovation engine to drive maximum customer value. Rajagopalan joined FourKites seven years ago as Chief Product Officer, bringing with her a wealth of experience in product management from various startups and public companies. Currently, Rajagopalan also serves on the Board of Directors of Brambles (ASX: BXB), the supply-chain logistics company operating across 60 countries through the CHEP brand. A testament to her industry contributions, she has been named an SDCE Pros to Know, and one of The Software Report’s Top 25 Software Product Executives.

Under Rajagopalan’s direction, FourKites has rolled out a number of industry-first product innovations, including real-time facility manager Dynamic Yard; end-to-end international ocean shipments tracker Dynamic Ocean; generative AI assistant Fin AI; patented AI-powered ETA forecaster Smart Forecasted Arrival; universal appointment scheduler Appointment Manager; and others.

“FourKites defined and created the supply chain visibility category, and innovating with customers has been, and continues to be part of our company’s DNA,” said Rajagopalan. “This alignment allows us to innovate and execute at even greater speed to ensure successful deployment and adoption across our customers."

Ron Richardson returns to FourKites as CRO, where he leads Sales, Partners and Alliances to drive FourKites’ global momentum. Ron recently served as CRO at OneRail, a solution that has redefined last-mile delivery, as well as CRO at Turvo, where he helped scale the company revenue and position it for a successful exit. Previously, Richardson was one of FourKites’ first employees, where he was instrumental in creating the real-time transportation visibility platform (RTTVP) category, building the business and closing some of the company’s earliest customer deals, including Coca-Cola, Nestlé and many more.

“I am thrilled to come back home to FourKites — returning to the market-leading company and the industry category I helped pioneer,” said Richardson. “I look forward to building on the momentum the team and I jump-started in the early years, driving growth and success among our Fortune 500 enterprise customers who continue to see massive value with the FourKites platform.”

“These promotions reflect our confidence in Priya’s and Ron’s leadership and their ability to propel FourKites to even greater heights,” said FourKites founder and CEO Mathew Elenjickal. “Priya’s unique blend of deep technical knowledge, innate leadership skills and collaborative approach has earned her admiration from industry leaders, investors and customers alike. Likewise, Ron brings deep industry experience, a strong track record as a successful CRO and, most importantly, vast knowledge of our existing customers and ecosystem. Under their leadership, we will continue to innovate, grow and solidify our position as the de-facto leader in the supply chain visibility space.”

About FourKites

Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,500 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314808596/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye